Page last updated: 2024-12-11

idb 1016

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6450536
SCHEMBL ID1649845
MeSH IDM0185662

Synonyms (7)

Synonym
silipide
idb-106
4h-1-benzopyran-4-one, 2-(2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-, (2r-(2alpha,3beta,6(2r*,3r*)))-, mixt. with soya phosphatidylcholines
idb 1016
134499-06-2
SCHEMBL1649845
[1-[(4e,9e,12e)-hexadeca-4,9,12-trienoyl]oxy-3-[(6e,10e,12e)-hexadeca-6,10,12-trienoyl]oxypropan-2-yl] 2-(trimethylazaniumyl)ethyl phosphate;(2r,3r)-3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-

Research Excerpts

Overview

IdB 1016 is a new silybin-phospholipid complex which is more bioavailable than the flavonoid sily bin itself. It displays free radical scavenging and antioxidant properties in liver microsomes.

ExcerptReferenceRelevance
"IdB 1016 is a new silybin-phospholipid complex which is more bioavailable than the flavonoid silybin itself and displays free radical scavenging and antioxidant properties in liver microsomes. "( Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016.
Albano, E; Carini, R; Comoglio, A; Poli, G, 1992
)
1.93
"IdB 1016 is a complex of silybin (the main active component of silymarin) and phosphatidylcholine, which in animal models shows greater oral bioavailability and therefore greater pharmacological activity compared with pure silybin and silymarin. "( Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.
Barzaghi, N; Crema, F; Gatti, G; Perucca, E; Pifferi, G,
)
1.87

Treatment

ExcerptReferenceRelevance
"Treatment with IdB 1016 is associated with reduced body iron stores, especially among patients with advanced fibrosis stage."( Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C.
Bares, JM; Berger, J; Kowdley, KV; Messner, DJ; Nelson, JE; Schildt, S; Standish, LJ, 2008
)
0.7

Pharmacokinetics

ExcerptReferenceRelevance
" In order to assess its pharmacokinetic profile in man, plasma silybin levels were determined after administration of single oral doses of IdB 1016 and silymarin (equivalent to 360 mg silybin) to 9 healthy volunteers."( Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.
Barzaghi, N; Crema, F; Gatti, G; Perucca, E; Pifferi, G,
)
0.63
"To develop a new HPLC-UV method of determining silybin in human plasma and to study the pharmacokinetic of silybin-phosphatidylcholine complex (silybinin capsules) in healthy male Chinese volunteers using the new developed method."( Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers.
Gao, J; Li, W; Liu, CX; Zhao, HZ,
)
0.13

Bioavailability

IdB 1016 is a complex of silybin and phosphatidylcholine. In animal models shows greater oral bioavailability and therefore greater pharmacological activity.

ExcerptReferenceRelevance
" These data indicate that the bioavailability of silybin is much greater after administration of silipide than after administration of silymarin."( Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients.
Gatti, G; Perucca, E; Schandalik, R, 1992
)
0.28
" Our results indicate a superior bioavailability of silybin administered orally as IdB 1016."( Comparative bioavailability of Silipide, a new flavanolignan complex, in rats.
Giachetti, C; Magistretti, MJ; Morazzoni, P; Zanolo, G,
)
0.36
"IdB 1016 is a complex of silybin (the main active component of silymarin) and phosphatidylcholine, which in animal models shows greater oral bioavailability and therefore greater pharmacological activity compared with pure silybin and silymarin."( Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.
Barzaghi, N; Crema, F; Gatti, G; Perucca, E; Pifferi, G,
)
1.87
" However, such an effect is lost when pure silybin in amounts comparable to those present in Silipide is administered instead, due to the low bioavailability of uncomplexed flavonoid."( Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals.
Albano, E; Comoglio, A; Malandrino, S; Poli, G; Tomasi, A, 1995
)
0.29
" The relative bioavailability of silipide (calculated in the target organ as the ratio between AUCs of cumulative biliary excretion curves) was 10-fold higher than that of silymarin."( Comparative pharmacokinetics of silipide and silymarin in rats.
Malandrino, S; Montalbetti, A; Morazzoni, P; Pifferi, G,
)
0.13
" We also aimed to establish the plasma and tumour bioavailability of silybin after repeated administration of IdB 1016."( Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer.
Apollonio, P; Bombardelli, E; Ferlini, C; Gallo, D; Giacomelli, S; Morazzoni, P; Prislei, S; Raspaglio, G; Riva, A; Scambia, G, 2003
)
0.77
"The aim of the present study was to evaluate the hepatoprotective and the antifibrotic properties of a new silybin-phosphatidylcholine-Vitamin E complex, characterised by elevated oral bioavailability and lipophilicity, on rat hepatic fibrosis induced by dimethylnitrosamine administration and by bile duct ligation."( Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats.
Bendia, E; Benedetti, A; Candelaresi, C; De Minicis, S; Di Sario, A; Marzioni, M; Omenetti, A; Taffetani, S, 2005
)
0.33
" The potential for enhanced bioavailability of a phytosome complex containing phosphatidylcholine and silybin, the primary active flavonolignan in silymarin extract, was tested in dogs."( Bioavailability of a silybin-phosphatidylcholine complex in dogs.
Filburn, CR; Griffin, DW; Kettenacker, R, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
"4 hours after dosing and declined thereafter with a half-life of about 2 hours."( Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers.
Gatti, G; Perucca, E, 1994
)
0.29
" A group of eight beagles (four males, four females) were dosed orally with a silybin-phosphatidylcholine complex (SPC) and a commercially available standardized silymarin extract containing equivalent levels of silybin."( Bioavailability of a silybin-phosphatidylcholine complex in dogs.
Filburn, CR; Griffin, DW; Kettenacker, R, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (47.37)18.2507
2000's9 (47.37)29.6817
2010's1 (5.26)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.82 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]